Hepatitis C Virus Diversity and Evolution in the Full Open-Reading Frame during Antiviral Therapy
Authors:
- Maureen J. DonlinMDMaureen J. Donlin
- Rajeev AuroraRARajeev Aurora
- John E. TavisJTJohn E. Tavis
- for the Virahep-C Study GroupFGfor the Virahep-C Study Group
Open Access
- 7 May 2008
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (5) , e2123
Abstract
Pegylated interferon plus ribavirin therapy for hepatitis C virus (HCV) fails in approximately half of genotype 1 patients. Treatment failure occurs either by nonresponse (minimal declines in viral titer) or relapse (robust initial responses followed by rebounds of viral titers during or after therapy). HCV is highly variable genetically. To determine if viral genetic differences contribute to the difference between response and relapse, we examined the inter-patient genetic diversity and mutation pattern in the full open reading frame HCV genotype 1a consensus sequences. Pre- and post-therapy sequences were analyzed for 10 nonresponders and 10 relapsers from the Virahep-C clinical study. Pre-therapy interpatient diversity among the relapsers was higher than in the nonresponders in the viral NS2 and NS3 genes, and post-therapy diversity was higher in the relapsers for most of HCV's ten genes. Pre-therapy diversity among the relapsers was intermediate between that of the non-responders and responders to therapy. The average mutation rate was just 0.9% at the amino acid level and similar numbers of mutations occurred in the nonresponder and relapser sequences, but the mutations in NS2 of relapsers were less conservative than in nonresponders. Finally, the number and distribution of regions under positive selection was similar between the two groups, although the nonresponders had more foci of positive selection in E2. The HCV sequences were unexpectedly stable during failed antiviral therapy, both nonresponder and relapser sequences were under selective pressure during therapy, and variation in NS2 may have contributed to the difference in response between the nonresponder and relapser groups. These data support a role for viral genetic variability in determining the outcome of anti-HCV therapy, with those sequences that are more distant from an optimal sequence being less able to resist the pressures of interferon-based therapy. ClinicalTrials.gov NCT00038974Keywords
This publication has 67 references indexed in Scilit:
- Hepatitis C Virus p7 and NS2 Proteins Are Essential for Production of Infectious VirusJournal of Virology, 2007
- Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to TherapyJournal of Virology, 2007
- Adaptation to Human Populations Is Revealed by Within-Host Polymorphisms in HIV-1 and Hepatitis C VirusPLOS Pathogens, 2007
- Evidence of Viral Adaptation to HLA Class I-Restricted Immune Pressure in Chronic Hepatitis C Virus InfectionJournal of Virology, 2006
- Efficient amplification and cloning of near full-length hepatitis C virus genome from clinical samplesBiochemical and Biophysical Research Communications, 2006
- Hepatitis C Virus–Specific Immune Responses and Quasi‐Species Variability at Baseline Are Associated with Nonresponse to Antiviral Therapy during Advanced Hepatitis CThe Journal of Infectious Diseases, 2006
- Mutations within the Hepatitis C Virus Genotype 1b E2-PePHD Domain Do Not Correlate with Treatment OutcomeJournal of Clinical Microbiology, 2005
- SWAPSC: sliding window analysis procedure to detect selective constraintsBioinformatics, 2004
- HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirinJournal of Hepatology, 2004
- Substrate Complexes of Hepatitis C Virus RNA Polymerase (HC-J4): Structural Evidence for Nucleotide Import and De-novo InitiationJournal of Molecular Biology, 2003